Skip to main content
. 2022 Jun 27;13:910582. doi: 10.3389/fimmu.2022.910582

Figure 3.

Figure 3

The identification and prognostic value assessment of ALXO12. (A, B) GO (A) and KEGG (B) enrichment analysis results of bevacizumab-related genes. (C) Bevacizumab-related genes with AUC >0.70. (D) Validation of the correlation between six-hub genes and bevacizumab response in four external cohorts and our internal cohort. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. (E) Kaplan–Meier survival analysis of the high and low ALOX12 expression groups in TCGA-CRC and GSE72970. (F) Multivariate Cox regression analysis of OS, RFS, and PFS in TCGA-CRC, GSE72970, and our cohort. ns, no significance.